SureTrader Nadex Advertisement PGUS
Home > Boards > US OTC > Medical - Healthcare >

Oxis International Inc. (OXIS)

OXIS RSS Feed
Add OXIS Price Alert      Hide Sticky   Hide Intro
Moderator: CashBowski
Search This Board: 
Last Post: 3/23/2017 5:59:18 PM - Followers: 167 - Board type: Free - Posts Today: 130


 

Oxis International Inc.

Below shows OXS-1550 WORKING - Soon to enter Phase II with FDA!

Overview

Treating Non-Hodgkin's lymphoma

OXS-1550 targets cancer cells expressing the CD19 receptor or CD22 receptor or both receptors. When OXS-1550 binds to cancer cells, the cancer cells internalize OXS-1550 and are killed due to the action of drug's cytotoxic payload. OXS-1550 has demonstrated success in early human clinical trials in patients with relapsed/refractory B-cell lymphoma or leukemia.

Treating triple-negative breast cancer

Our lead drug candidate, OXS-2175, is a small molecule therapeutic candidate targeting the treatment of triple-negative breast cancer. In in vitro and in vivo models of TNBC, OXS-2175 demonstrated the ability to inhibit metastasis.

Treating multiple myeloma

Our lead drug candidate, OXS-4235, also a small molecule therapeutic candidate, targets the treatment of multiple myeloma and associated osteolytic lesions. In in vitro and in vivo models of multiple myeloma and osteoporosis, OXS-4235 demonstrated the ability to kill multiple myeloma cells, and decrease osteolytic lesions in bone.


Management



 

Company Website
http://oxis.com

 


Corporate Overview - Presentation
Fall 2015
Click the link: http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=10968247


 




 





 

 

OXIS Conference Call  March 31, 2015

CEO Interview with The Wolf of Weedstreet

 

SCIENTIFIC ADVISORY BOARD

XIANG-QUN (SEAN) XIE, M.D., Ph.D., EMBA

Sean Xie, MD, PhD, EMBA is a tenured Professor at the Department of Pharmaceutical Sciences/Drug Discovery Institute at University of Pittsburgh and Associate Dean for Research Innovation at the School of Pharmacy. He is Principal Investigator of an integrated research laboratory of CompuGroup, BioGroup and ChemGroup, and Founding Director of Computational Chemical Genomics Screening Center. Dr. Xie is also Director/PI of NIH funded National Center of Excellence for Computational Drug Abuse Research. Dr. Xie holds joint faculty positions at the Departments of Computational System Biology and Structural Biology, and Pittsburgh Cancer Institute MT/DD Program. He serves as an invited guest editor for AAPS Journal, Editorial Board of American Journal of Molecular Biology, and Associate Editor of BMC Pharmacology and Toxicology. In 2013, he was named an honorary professor of Chinese Academy of Medical Sciences & Peking Union Medical College. Dr. Xie is a recipient of the 2014 American Association of Pharmaceutical Scientists (AAPS) Outstanding Research Achievement Award.

JAMES J. MULE, Ph.D.

Dr. James J. Mule, Ph.D. serves as an Executive Vice President and Associate Center Director for Translational Research, the Michael McGillicuddy Endowed Chair for Melanoma Research and Treatment, and the Co-Director of the Donald A. Adam Comprehensive Melanoma Center at the Moffitt Cancer Center. He then moved to Palo Alto, Calif., where he was involved in the birth of two startup companies while an adjunct faculty member in the Department of Surgery, Stanford University. He moved to Ann Arbor, Mich., as the Director of the Tumor Immunology and Immunotherapy Clinical Research Programat the University of Michigan Comprehensive Cancer Center. Dr. Mule is recognized for his translational research studies in cancer immunotherapy. His research group is involved in vaccine strategies and other approaches to stimulate the immune system to recognize and destroy tumors. The work in these areas has helped to develop new treatments for advanced cancer patients. Dr. Mule serves on the Advisory Boards of seven NCI-designated Cancer Centers and was a member of the NCI’s Board of Scientific and Clinical Counselors. He serves as Chair of the Cellular, Tissue and Gene Therapy Advisory Committee of CBER, FDA, is a Special Government Employee of the NCI and the FDA. Dr. Mule is recognized for his research and clinical contributions to cancer immunotherapy, particularly in solid tumors.

STEPHEN M. CHANG, Ph.D.

Dr. Stephen M. Chang is Vice President-Research & Development at New York Stem Cell Foundation, Chief Scientific Officer at Stemgent, Inc., and Independent Director at MultiCell Technologies, Inc. He is on the Board of Directors at MultiCell Technologies, Inc. Dr. Chang was previously employed as Chief Scientific Officer & Vice President by Canji, Inc., Chief Scientific Officer & Vice President by Schering-Plough Research Institute, and President & Chief Executive Officer by MultiCell Immunotherapeutics, Inc. He also served on the board at Histogen, Inc. He received his undergraduate degree from the University of Michigan and a doctorate degree from the University of California, Irvine.

LISA A. HAILE, Ph.D.

Dr. Haile has special technical experience in molecular biology, immunology, plant biotechnology, including transgenic plants, cell biology, diagnostics, therapeutics, theranostics, virology, drug delivery systems, host-vector systems, high throughput screening and bioinformatics. She has particular experience with patentability, non-infringement and validity opinions; licensing strategies; FDA counseling; due diligence work in connection with venture capital, private and public financing; mergers and acquisitions in the life sciences industry; and strategic counseling for comprehensive life sciences patent portfolio management. Dr. Lisa Haile concentrates on patent protection.

 

Information on Multiple Myeloma & Cannabidiol (CBD)

After studying the effects of cannabidiol on multiple myeloma cells, researchers found that; “CBD by itself or in synergy with BORT strongly inhibited growth, arrested cell cycle progression and induced MM cells death by regulating the ERK, AKT and NF-κB pathways with major effects in TRPV2+ cells.”

They conclude that; “These data provide a rationale for using CBD to increase the activity of proteasome inhibitors in MM.”

The study, which validates a recent National Institute of Health study which also found that cannabidiol can inhibit cancer cells, was conducted by researchers at the School of Pharmacy at the University of Camerino in Italy.

 Chart

Stock Information:


 
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
OXIS
Current Price
Volume:
Bid Ask Day's Range
SureTrader
OXIS News: Current Report Filing (8-k) 05:17 PM
OXIS News: Current Report Filing (8-k) 03/02/2017 04:47:01 PM
OXIS News: Current Report Filing (8-k) 02/17/2017 05:17:13 PM
OXIS News: Amended Statement of Ownership (sc 13g/a) 02/13/2017 01:42:09 PM
OXIS News: Securities Registration Statement (s-1/a) 02/10/2017 05:22:26 PM
News News Alert: Current Report Filing (8-k) 03/23/2017 05:17:24 PM
PostSubject
#9279   adding debt and interest, they got their shares bilrip 03/23/17 06:07:52 PM
#9278   Once the note selling ends, it will be chigurh 03/23/17 05:59:18 PM
#9277   More than half of all outstanding shares traded Market Analysis LLC 03/23/17 05:54:32 PM
#9276   Exactly. Case and point. PLSB today. mkt_predictor 03/23/17 05:47:06 PM
#9275   At least someone is getting their money back. scoot27 03/23/17 05:46:02 PM
#9274   Yes still small and probably they sold most trader993 03/23/17 05:44:31 PM
#9273   He should wait for .002, PLBS dilution is trader993 03/23/17 05:42:38 PM
#9272   Dont beat yourself up for that, $PLS& only chigurh 03/23/17 05:38:41 PM
#9271   o/s still small mean weimeraner 03/23/17 05:32:54 PM
#9270   I was looking at this and PLSB last 2014turnaround 03/23/17 05:23:19 PM
#9269   8-k is out: trader993 03/23/17 05:12:35 PM
#9268   I'm just here to make money. Not marry Superman 03/23/17 05:09:55 PM
#9267   This is the key, not the absurd valuations chigurh 03/23/17 05:08:21 PM
#9266   Sorry, if you don´t see the difference between trader993 03/23/17 05:08:08 PM
#9265   Grabbed a starter here today. Hoping their mkt_predictor 03/23/17 05:06:54 PM
#9264   Wow. You're right. Let me notify the planet Superman 03/23/17 05:06:46 PM
#9263   Look at the 1 and 3 yr chart Halks1122 03/23/17 05:06:27 PM
#9262   I would estimate that I have read similar chigurh 03/23/17 05:06:00 PM
#9261   They went through phase 1, this was completed. trader993 03/23/17 05:05:03 PM
#9260   I never called anyone an idiot. I listened Halks1122 03/23/17 05:04:58 PM
#9259   lol, always an indicator of legitimacy. chigurh 03/23/17 05:00:00 PM
#9258   Please, name 3 penny stocks that claim to willy bob 03/23/17 04:55:10 PM
#9257   You'd have like $1 willy bob 03/23/17 04:53:42 PM
#9256   What i see, phase 1/2 FDA clinical trial, trader993 03/23/17 04:52:23 PM
#9255   I wish I had a nickel for every Superman 03/23/17 04:50:58 PM
#9254   I see. But we must also realize you chigurh 03/23/17 04:50:32 PM
#9253   I see in your post history you bought trader993 03/23/17 04:46:08 PM
#9252   You are wrong sunshine as always :) BondAssets 03/23/17 04:43:48 PM
#9251   I am in part ownership with oxis as BondAssets 03/23/17 04:38:21 PM
#9250   I have been trading this stock (only going willy bob 03/23/17 04:38:14 PM
#9249   Damn you been on this crusade since early chigurh 03/23/17 04:21:43 PM
#9248   1. Just because I sold some, doesn't jdporter 03/23/17 04:15:43 PM
#9247   Anyone who thinks this has hope is delirious. Halks1122 03/23/17 04:15:00 PM
#9246   I am personally saddened by the losses here. simon wagstaff 03/23/17 04:13:08 PM
#9245   Sold half my position...potential is still here but jdporter 03/23/17 03:58:48 PM
#9244   lol absolute crap festival. Notes are like a chigurh 03/23/17 03:49:44 PM
#9243   OXIS LONGS! jimbosskow 03/23/17 03:39:35 PM
#9242   *measly $200k. Gotta love the iPhone ;-) rockman213 03/23/17 03:37:56 PM
#9241   Traded a measles $20k today. That's why the rockman213 03/23/17 03:33:46 PM
#9240   2s up at least jdporter 03/23/17 03:20:19 PM
#9239   The SP is the true value of Oxis. simon wagstaff 03/23/17 03:04:41 PM
#9238   Nope ARCA ball kicks OXIS share holders again. chigurh 03/23/17 03:04:10 PM
#9237   L2 looking cleaner perhaps? Do not forsake me L2. chigurh 03/23/17 02:57:07 PM
#9235   look at the L2 lol mean weimeraner 03/23/17 02:51:24 PM
#9234   Look at the SP, the market cap, the simon wagstaff 03/23/17 02:48:01 PM
#9233   Oxis and the University of Minnesota have reached BondAssets 03/23/17 02:39:55 PM
#9232   Sure is, when the OS was 24M 8 m931a1 03/23/17 02:34:54 PM
#9230   Exactly. Superman 03/23/17 02:06:45 PM
#9229   Not at all. When faucet is finally shut bilrip 03/23/17 02:03:21 PM
#9228   100 million OS is nothing. Superman 03/23/17 02:00:52 PM
PostSubject